MedTrace Logo

Safety and Efficacy Study of CC-122 Combined With Sorafenib for Primary Liver Cancer

NCT02323906 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 12

Last updated 2017-03-20

No results posted yet for this study

Summary

CC-122-HCC-001 is a Phase 1b dose escalation and expansion clinical study of CC-122 in combination with sorafenib for subjects with unresectable HCC who have received no prior systemic therapy for HCC. The dose escalation phase of the study will explore several dose levels of CC-122 in combination with sorafenib, followed by an expansion part of the study using the optimal combination dose regimen.

Conditions

  • Carcinoma, Hepatocellular

Interventions

DRUG

CC-122

Investigational new drug

DRUG

Sorafenib

Kinase inhibitor

Sponsors & Collaborators

  • Celgene

    lead INDUSTRY

Principal Investigators

  • Kristen Hege, MD · Celgene Corporation

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-01-16
Primary Completion
2016-12-21
Completion
2016-12-21

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02323906 on ClinicalTrials.gov